中东和非洲 Blau 综合征市场 – 行业趋势和 2030 年预测

中东和非洲 Blau 综合症市场分析和规模

布劳综合征医疗保健行业的多项进步将影响多家制造商向市场推出新产品，提高其需求以及非处方药的供应。此外，日新月异的技术也阻碍了医生进行多种基因测试。目前，正在进行大量研究，预计这将为制造商创造竞争优势，以开发先进和创新的布劳综合征药物，预计这将为布劳综合征市场提供其他机会。

 Data Bridge Market Research 分析了 2023-2030 年预测期内 blau 综合征市场的增长率。在上述预测期内，blau 综合征市场的预期复合年增长率趋于 8.8% 左右。2022 年市场价值为 11 万美元，到 2030 年将增长至 22 万美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

中东和非洲布劳综合征市场范围和细分

市场定义

Blau Syndrome typically presents in childhood with granulomatous dermatitis, arthritis, and uveitis. This syndrome is also termed as familial juvenile systemic granulomatosis. Even though a skin rash is not necessarily a ubiquitous feature of Blau syndrome, it is mostly the first sign of disease if it is available. In majority of the cases, a normal rash appears within the first year of life and presents as discrete, erythematous papules. In this condition, the most common feature which is arthritis, tends to rise between the ages of 2 to 4 years.

Middle East and Africa Blau Syndrome Market Dynamics

Drivers

• Increasing Diagnostic Procedures

There have been increasing diagnostic procedures available which boosts the market growth. Optical coherence tomography (OCT) may be used to depict the extent of ocular disease. Skin or synovial biopsy may be used that will reveal noncaseating granulomas. Out of these two options, skin biopsy is less invasive and has showed higher accuracy. Furthermore, next generation sequencing may be used to test for causative NOD2 mutations, that will confirm the diagnosis. X-rays show dysplastic changes, such as camptodactyly, carpal dysplasia, abnormal ulna and second metacarpal bone shape, abnormal distal radial epiphysis, short ulna. Complete blood count (CBC), C-reactive protein (CRP), serum angiotensin-converting enzyme (ACE), erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), anti-neutrophilic cytoplasmic antibody (ANCA), anti-dsDNA antibody, Lyme disease serology, rheumatoid factor (RF),  RPR/VDRL, human leukocyte antigen (HLA) testing, tuberculin skin test, pathergy skin test are the types of tests that can be performed.

Opportunities

• Growing Treatment Options

Treatment options such as corticosteroids also have utility during quiescent periods. The prolonged need for corticosteroids, along with the frequency of refractory symptoms, signifies the use of immunosuppressants such as mycophenolate mofetil, methotrexate, or azathioprine. For this reason, the wide use of monoclonal antibodies to target these cytokines has become helpful; though, variable degrees of efficacy have been witnessed in the literature. It is difficult to determine the true therapeutic benefit of these agents due to contrasting results and the relatively scarce amount of data available. Though medical management is the keystone of treatment for patients with Blau syndrome, operative intervention is also used in certain scenarios. There are many ocular diseases, wherein many inflammatory sequelae should be addressed surgically. Patients may opt to undergo joint fusion procedures because of severe, unrelenting arthritis. Thus, this boosts the market growth.

Restraints/Challenges

• Unavailability of skilled professionals

The wide unavailability of qualified professionals who cannot treat the patients with appropriate treatments could restrict the market growth during the forecast period 2023-2030.

• High Cost of Treatment

The increasing expenditure related with medications hinder the market growth. These inhibitors cost high and people in the developing and underdeveloped countries can lead to the under treatment of numerous patients. This hinders the market growth.

This blau syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blau syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Middle East and Africa Blau Syndrome Market Scope

The blau syndrome market is segmented on the basis of therapeutic areas, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Areas

• Skin Rash
• Inflammation

Route of Administration

• Oral
• Parenteral
• Topical
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Blau Syndrome Market Regional Analysis/Insights

The blau syndrome market is analyzed and market size insights and trends are provided by therapeutic areas, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the blau syndrome market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Saudi Arabia is leading the market as numerous companies are investing in the country in upcoming years. This includes heavy investments in R&D along with infrastructure for providing medical services. Furthermore, several manufacturers in the autoimmune disorders market are providing huge range of products that increases the market growth as well.

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析的同时，还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和中东及非洲布劳综合征市场份额分析

布劳综合征市场竞争格局按竞争对手提供详细信息。 详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、中东和非洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。 以上提供的数据点仅与公司对布劳综合征市场的关注有关

在 Blau 综合症市场运营的主要参与者包括：

• Abbvie, Inc（美国）
• 诺华公司（瑞士）
• 梯瓦制药工业有限公司 (以色列)
• 辉瑞公司（美国）
• 安进公司 (美国)
• Janssen Global Services, LLC（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Hikma Pharmaceuticals PLC（英国）
• Fulgent Genetics（美国）
• Invitae Corporation（美国）
• 瑞典孤儿药 Biovitrum AB（瑞典）
• Alkem Labs Ltd（印度）
• Accord Healthcare（英国）
• Zydus 集团 (印度)
• Amneal Pharmaceutical Inc.（英国）
• CENTOGENE NV（德国）

SKU-55594